PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17892613-11	2008	Tissue myeloperoxidase (MPO) enzyme activity was significantly higher in the non-treated group than in the levosimendan-treated group (P = 0.004).	Simendan	107-119	myeloperoxidase	Rattus norvegicus	7-22	
17892613-11	2008	Tissue myeloperoxidase (MPO) enzyme activity was significantly higher in the non-treated group than in the levosimendan-treated group (P = 0.004).	Simendan	107-119	myeloperoxidase	Rattus norvegicus	24-27	
34213003-10	2021	Histopathological injury score, plasma MPO, AST, ALT, tissue MPO and tissue MDA values were statistically significantly lower in the treatment groups, prominently in the levosimendan and NAS combination group concerning liver histopathological damage.	Simendan	170-182	myeloperoxidase	Rattus norvegicus	39-42	
34788887-10	2022	LEV co-treatment could increase mitochondrial complex activity and reduce MPO activity, LPO, ROS, and lactate levels.	Simendan	0-3	myeloperoxidase	Rattus norvegicus	74-77	
34213003-10	2021	Histopathological injury score, plasma MPO, AST, ALT, tissue MPO and tissue MDA values were statistically significantly lower in the treatment groups, prominently in the levosimendan and NAS combination group concerning liver histopathological damage.	Simendan	170-182	myeloperoxidase	Rattus norvegicus	61-64